Express Pharma

Beyond expiry dates: Building a more transparent and traceable medicine supply chain 

Devashish Singh, Co-founder and CEO of MrMed, highlights how end-to-end medicine traceability can strengthen supply-chain accountability, improve medicine safety and ensure critical medicines can be tracked from manufacturer to patient 

0 4

A medicine does not become a patient-safety risk only when it crosses its expiry date. The risk can begin much earlier, when its source cannot be verified, when a batch cannot be traced, when storage conditions are unknown, or when a product recalled by the manufacturer cannot be reliably located across the supply chain. 

India has made significant progress in putting systems in place to address some of these challenges. QR and barcode based identification have been part of the regulatory framework for several years, and the government has recently expanded the traceability framework to cover critical categories including anti-cancer medicines, vaccines and antimicrobials. Under the amended framework, these products will carry QR or barcodes containing key information such as product identification, manufacturer, batch number, manufacturing and expiry dates, and licensing details. 

The next challenge is not creating more traceability infrastructure. It is ensuring that the information captured at the manufacturing stage remains usable and verifiable all the way to the point where a medicine reaches a patient. 

That distinction matters. A medicine may pass through manufacturers, distributors, warehouses, pharmacies and hospitals before it is finally dispensed. At each stage, its identity, batch, expiry, storage conditions and ownership can potentially become less visible. When that happens, even a well-regulated product can become difficult to track when something goes wrong. 

For ordinary medicines, this can lead to avoidable wastage, stock-outs or inefficient inventory management. For oncology, biologics, transplant and rare-disease therapies, the consequences can be considerably more serious. India has the technology to track medicines. The open question is whether the industry can make traceability a continuous responsibility, from manufacturer to patient, rather than a set of checkpoints along the way. 

Where batch-level tracking breaks down 

Most pharmacies, hospitals and distributors record a purchase and a sale. Far fewer consistently capture the batch number and expiry date at both ends of that transaction, and fewer still reconcile the two.

A medicine is a traceable unit with a specific manufacturing history, shelf life and chain of custody, not just a product. Once batch identity is lost at any point, everything downstream becomes harder to verify. A recall cannot be executed with precision, nearexpiry stock cannot be proactively moved or removed, and a suspicious pack becomes difficult to distinguish from a genuine one. 

Strengthening this does not necessarily require another layer of complexity. It requires making existing practices non-negotiable. 

Batch number and expiry should be captured when goods are received rather than reconstructed later from invoices. Inventory should follow a strict first-expiry-first-out principle, with systems preventing a dispense that violates it rather than merely flagging the issue afterwards. Physical stock should be reconciled against digital records at defined intervals, and discrepancies should trigger investigation. 

Procurement is equally important. Pharmacies and hospitals should source medicines only from manufacturers or authorised distributors, with invoices and batch details that can be traced back through the supply chain. 

For hospitals, this discipline needs to extend beyond the central pharmacy. Ward-level inventories, emergency stocks and crash carts also need the same level of visibility, because a medicine that is correctly tracked in a warehouse can still become a patient-safety risk if its expiry is not monitored once it reaches the point of care. 

Authenticity is only one part of the equation 

Traceability is often discussed in the context of counterfeit medicines, but authenticity is only one part of the problem. A medicine can be genuine when it leaves the manufacturer and still become unsuitable for use if it is improperly stored, mishandled or allowed to cross its expiry date. 

This is particularly important for temperature-sensitive therapies. A product that has been exposed to conditions outside its prescribed cold chain may look no different from a properly stored product. The packaging does not necessarily tell the patient what happened to the medicine between manufacturing and dispensing. 

That is why end-to-end traceability needs to include more than a batch number. Where storage conditions are critical, temperature and handling records should also form part of the chain of custody and be available when required. 

For the patient, the question should ultimately be simple. Can the authenticity, provenance, storage history and expiry status of a critical medicine be established with confidence? Today, that answer is not always yes. 

Why expiry management matters even more for super-specialty medicines 

Expiry management becomes particularly consequential when dealing with super-specialty and life-saving therapies. 

Oncology medicines, biologics, transplant therapies and rare-disease treatments can be extremely expensive, temperature-sensitive and clinically critical. They are also often prescribed as part of tightly sequenced treatment regimens where delays or interruptions can have serious consequences. 

For these medicines, the issue is not simply financial wastage. A medicine nearing expiry may technically remain within its labelled shelf life, but that does not necessarily make it appropriate for every patient or treatment schedule. A patient beginning a long term therapy should not be handed stock with an impractically short remaining shelf life. 

The industry needs to move from asking whether a medicine is expired to asking whether it is fit, authentic, properly stored and appropriate for the intended treatment window. 

This is where minimum remaining-shelf-life thresholds can play a role, particularly for high-value and critical therapies. Cold-chain compliance should also be demonstrable rather than assumed simply because a shipment arrived cold. 

For patients and caregivers, these may appear to be backend supply-chain issues. In reality, they directly influence treatment continuity and patient safety.

The gaps in the current medicine supply chain 

Three gaps require particular attention. 

The first is reverse logistics. Medicines move down the supply chain with relatively detailed documentation, but expired, damaged and returned stock can move back with considerably less visibility. That creates an opportunity for diversion, repackaging and reentry into the legitimate market. The answer is to treat reverse logistics with the same seriousness as forward distribution. Every returned or expired batch should have a documented status, location and final disposition. 

The second is the last mile. Unlicensed sellers, unverified online listings and retailers sourcing from unknown channels create points in the system where the provenance of medicines becomes difficult to establish. Stronger procurement controls and more frequent verification are required at these points. 

The third is fragmented use of traceability infrastructure. India is now expanding QR-based traceability to more critical medicine categories, but the value of such infrastructure will ultimately depend on how consistently the information is accessed and acted upon across the supply chain. A traceability system that records information but does not use it to make decisions is only partially solving the problem. 

What pharmacies, hospitals and distributors can do 

The industry does not need to wait for every regulatory requirement to take effect. 

Pharmacies can strengthen batch-level inventory by recording batch and expiry information at inward and dispensing stages, implementing first-expiry-first-out systems and conducting regular physical reconciliation. Distributors can improve visibility by maintaining batchlevel records through both forward and reverse logistics, ensuring that returned or damaged stock is appropriately quarantined and disposed of, and limiting procurement to verified channels. Hospitals can extend these practices into wards, emergency departments and other locations where medicines may be stored outside the central pharmacy. 

For critical therapies, the ability to establish not only where a product came from but also how it was stored can be particularly important. These are operational changes, but they can have a direct impact on patient safety. 

What regulators can do next 

The recent expansion of QRbased traceability is an important step. The government has now brought vaccines, antimicrobials, anti-cancer medicines and specified narcotic and psychotropic drugs under the expanded framework, with phased implementation timelines beginning in 2027. 

The next step is ensuring that this infrastructure creates an actionable, connected system rather than another compliance requirement. 

First, QR-based traceability should progressively cover more medicines, with priority given to high-value, temperature-sensitive and clinically critical therapies. 

Second, verification should happen at meaningful points in the supply chain. Pharmacies, hospitals and other licensed dispensing points should be encouraged, and for higher-risk categories, potentially required, to scan and verify medicines before dispensing. A code that exists on a package but is never checked provides limited protection. 

Third, India needs a more centralised and real-time recall mechanism. When a particular batch is found to be defective, spurious or unsafe, information should reach licensed pharmacies, hospitals and distributors quickly and in a standardised format. Batch level alerts can help reduce the dependence on information moving manually through multiple layers of the supply chain.

Fourth, the disposal loop needs to be closed. Expired medicines should move through authorised disposal channels, with destruction or disposal documented against the original batch. This matters because expired and returned stock can otherwise become a source of material for fraudulent repackaging. 

Finally, enforcement needs to focus on vulnerable points in the chain. Warehouses, distribution facilities and other high-risk nodes need appropriate licensing checks, audit mechanisms and inspection frequency. The objective should not only be to identify violations after they occur, but to make diversion and reentry increasingly difficult.

From compliance to accountability 

None of these interventions depends on technology that does not yet exist. The infrastructure for barcoding, digital inventory management, batchlevel tracking and QR-based verification is already available, and its regulatory scope is expanding.

The larger shift required is operational. The industry needs to treat batch and expiry information as a living part of a medicine’s identity, not data recorded once and forgotten. Pharmacies need to verify what they receive, hospitals need visibility beyond their central stores, and distributors need stronger controls over forward and reverse movement. Manufacturers need greater visibility into where products ultimately travel, and regulators need systems that connect these individual points into a more coherent chain. 

Medicine safety is not determined only at the point of manufacture. It is protected, or compromised, at every handover that follows. 

The goal should be bigger than preventing the sale of expired medicine. It should be a supply chain where every critical medicine can be authenticated, its batch and expiry can be verified, its handling can be traced, and its movement can be accounted for from manufacturer to patient. That is the level of transparency and accountability that patient safety demands. 

 

Leave A Reply

Your email address will not be published.